Telo Genomics Corp
3D0A
Company Profile
Business description
Telo Genomics Corp is developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Contact
1060 Quebec Street
VancouverBCV6A4K8
CANT: +1 647 477-9365
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2027
Employees
6
Stocks News & Analysis
stocks
What a wobby AI trade could mean for Anthropic's IPO
Despite recent AI jitters, strategists expect strong demand for Anthropic’s potentially historic IPO.
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
What inflation-resistant businesses have in common.
stocks
Our view after REA’s share price rally
A bullish market reaction but valuation concerns remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.40 | 18.70 | 0.20% |
| CAC 40 | 8,139.00 | 66.37 | -0.81% |
| DAX 40 | 25,820.36 | 504.65 | -1.92% |
| Dow JONES (US) | 51,285.73 | 237.33 | -0.46% |
| FTSE 100 | 10,673.94 | 108.72 | -1.01% |
| HKSE | 24,475.03 | 6.83 | -0.03% |
| NASDAQ | 24,579.43 | 264.43 | 1.09% |
| Nikkei 225 | 58,775.50 | 1,340.73 | 2.33% |
| NZX 50 Index | 13,973.62 | 24.88 | -0.18% |
| S&P 500 | 7,376.86 | 23.13 | 0.31% |
| S&P/ASX 200 | 9,029.70 | 8.90 | 0.10% |
| SSE Composite Index | 3,660.79 | 11.61 | 0.32% |